35,650 Shares in Zoetis Inc. $ZTS Bought by Clark Estates Inc. NY

Clark Estates Inc. NY acquired a new stake in Zoetis Inc. (NYSE:ZTS – Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 35,650 shares of the company’s stock, valued at approximately $2,489,000.

Several other institutional investors and hedge funds have also made changes to their positions in ZTS. South Dakota Investment Council increased its stake in shares of Zoetis by 5.8% during the third quarter. South Dakota Investment Council now owns 624,249 shares of the company’s stock valued at $43,591,000 after acquiring an additional 34,147 shares during the period. Rothschild Investment LLC acquired a new stake in Zoetis in the third quarter worth approximately $112,000. Sompo Asset Management Co. Ltd. lifted its position in Zoetis by 33.9% in the third quarter. Sompo Asset Management Co. Ltd. now owns 5,731 shares of the company’s stock worth $400,000 after purchasing an additional 1,451 shares during the period. First Eagle Investment Management LLC bought a new position in Zoetis during the 3rd quarter valued at $50,679,000. Finally, Cullen Capital Management LLC boosted its stake in Zoetis by 1.2% during the 3rd quarter. Cullen Capital Management LLC now owns 11,284 shares of the company’s stock valued at $788,000 after purchasing an additional 132 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on ZTS. Piper Sandler dropped their price objective on Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, August 10th. Zacks Research raised Zoetis from a “strong sell” rating to a “hold” rating in a research note on Monday, October 26th. Morgan Stanley lowered their target price on Zoetis from $85.00 to $82.00 and set an “overweight” rating on the stock in a report on Thursday, October 29th. Cantor Fitzgerald set a $94.00 price target on shares of Zoetis in a research report on Tuesday, August 25th. Finally, UBS Group upped their price target on shares of Zoetis from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Tuesday, October 27th. Eight analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and an average target price of $101.25.

Get Our Latest Stock Report on ZTS

Zoetis Price Performance

NYSE ZTS opened at $83.32 on Wednesday. Zoetis Inc. has a 1 year low of $68.77 and a 1 year high of $132.49. The business’s fifty day moving average is $76.64 and its two-hundred day moving average is $91.18. The stock has a market capitalization of $33.85 billion, a P/E ratio of 14.17, a P/E/G ratio of 1.22 and a beta of 0.67. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.40 and a current ratio of 2.35.

Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported $1.75 earnings per share for the quarter, topping the consensus estimate of $1.51 by $0.24. The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. The company’s revenue was down 1.3% compared to the same quarter last year. During the same period last year, the company posted $1.70 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.29 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s dividend payout ratio is currently 36.05%.

Zoetis Profile

(Free Report)

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

Featured Articles

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.